BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 20004582)

  • 1. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour.
    Lau EW; Drummond KJ; Ware RE; Drummond E; Hogg A; Ryan G; Grigg A; Callahan J; Hicks RJ
    J Clin Neurosci; 2010 Jan; 17(1):43-9. PubMed ID: 20004582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of (18)F-FET and (18)F-FDG PET in brain tumors.
    Pauleit D; Stoffels G; Bachofner A; Floeth FW; Sabel M; Herzog H; Tellmann L; Jansen P; Reifenberger G; Hamacher K; Coenen HH; Langen KJ
    Nucl Med Biol; 2009 Oct; 36(7):779-87. PubMed ID: 19720290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of 18F-FET PET in newly diagnosed cerebral lesions suggestive of glioma.
    Rapp M; Heinzel A; Galldiks N; Stoffels G; Felsberg J; Ewelt C; Sabel M; Steiger HJ; Reifenberger G; Beez T; Coenen HH; Floeth FW; Langen KJ
    J Nucl Med; 2013 Feb; 54(2):229-35. PubMed ID: 23232275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial 18F-FET PET Imaging of Primarily 18F-FET-Negative Glioma: Does It Make Sense?
    Unterrainer M; Schweisthal F; Suchorska B; Wenter V; Schmid-Tannwald C; Fendler WP; Schüller U; Bartenstein P; Tonn JC; Albert NL
    J Nucl Med; 2016 Aug; 57(8):1177-82. PubMed ID: 27033893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma.
    Bette S; Gempt J; Delbridge C; Kirschke JS; Schlegel J; Foerster S; Huber T; Pyka T; Zimmer C; Meyer B; Ringel F
    World Neurosurg; 2016 May; 89():230-9. PubMed ID: 26855307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.
    Prat R; Galeano I; Lucas A; Martínez JC; Martín M; Amador R; Reynés G
    J Clin Neurosci; 2010 Jan; 17(1):50-3. PubMed ID: 19959364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FET PET differentiation of ring-enhancing brain lesions.
    Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
    J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of F-18-labeled amino acid derivatives and [18F]FDG as PET probes in a brain tumor-bearing animal model.
    Wang HE; Wu SY; Chang CW; Liu RS; Hwang LC; Lee TW; Chen JC; Hwang JJ
    Nucl Med Biol; 2005 May; 32(4):367-75. PubMed ID: 15878506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An interindividual comparison of O-(2-[18F]fluoroethyl)-L-tyrosine (FET)- and L-[methyl-11C]methionine (MET)-PET in patients with brain gliomas and metastases.
    Grosu AL; Astner ST; Riedel E; Nieder C; Wiedenmann N; Heinemann F; Schwaiger M; Molls M; Wester HJ; Weber WA
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1049-58. PubMed ID: 21570201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a place for FET PET in the initial evaluation of brain lesions with unknown significance?
    Pichler R; Dunzinger A; Wurm G; Pichler J; Weis S; Nussbaumer K; Topakian R; Aigner RM
    Eur J Nucl Med Mol Imaging; 2010 Aug; 37(8):1521-8. PubMed ID: 20396883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of O-(2-[18F]fluoroethyl)- L-tyrosine PET for the diagnosis of recurrent glioma.
    Pöpperl G; Götz C; Rachinger W; Gildehaus FJ; Tonn JC; Tatsch K
    Eur J Nucl Med Mol Imaging; 2004 Nov; 31(11):1464-70. PubMed ID: 15248032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas.
    Pauleit D; Floeth F; Hamacher K; Riemenschneider MJ; Reifenberger G; Müller HW; Zilles K; Coenen HH; Langen KJ
    Brain; 2005 Mar; 128(Pt 3):678-87. PubMed ID: 15689365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of 18F-FDG, 11C-Methionine, and 18F-FET PET for Glioma Grading: A Meta-analysis.
    Katsanos AH; Alexiou GA; Fotopoulos AD; Jabbour P; Kyritsis AP; Sioka C
    Clin Nucl Med; 2019 Nov; 44(11):864-869. PubMed ID: 31205150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of (18)F-fluoroethyl-L: -tyrosine PET and magnetic resonance diffusion tensor imaging.
    Stadlbauer A; Pölking E; Prante O; Nimsky C; Buchfelder M; Kuwert T; Linke R; Doelken M; Ganslandt O
    Acta Neurochir (Wien); 2009 Sep; 151(9):1061-9. PubMed ID: 19468675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of 18F-FET PET and perfusion-weighted MR imaging: a PET/MR imaging hybrid study in patients with brain tumors.
    Filss CP; Galldiks N; Stoffels G; Sabel M; Wittsack HJ; Turowski B; Antoch G; Zhang K; Fink GR; Coenen HH; Shah NJ; Herzog H; Langen KJ
    J Nucl Med; 2014 Apr; 55(4):540-5. PubMed ID: 24578243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in the evaluation of glioma.
    Shaw TB; Jeffree RL; Thomas P; Goodman S; Debowski M; Lwin Z; Chua B
    J Med Imaging Radiat Oncol; 2019 Oct; 63(5):650-656. PubMed ID: 31368665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of
    He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
    BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods?
    Pöpperl G; Kreth FW; Herms J; Koch W; Mehrkens JH; Gildehaus FJ; Kretzschmar HA; Tonn JC; Tatsch K
    J Nucl Med; 2006 Mar; 47(3):393-403. PubMed ID: 16513607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FET PET in the evaluation of indeterminate brain lesions on MRI: Differentiating glioma from other non-neoplastic causes - A pilot study.
    Chan DL; Hsiao E; Schembri G; Bailey DL; Roach PJ; Lee A; Jayamanne D; Ghasemzadeh M; Hayes A; Cook R; Parkinson J; Drummond JP; Ibbett I; Wheeler HR; Back M
    J Clin Neurosci; 2018 Dec; 58():130-135. PubMed ID: 30243602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.